OmerosOMER
OMER
About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Employees: 198
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
4% more funds holding
Funds holding: 104 [Q2] → 108 (+4) [Q3]
0.22% less ownership
Funds ownership: 43.41% [Q2] → 43.19% (-0.22%) [Q3]
3% less capital invested
Capital invested by funds: $102M [Q2] → $99.3M (-$2.83M) [Q3]
26% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 35
58% less call options, than puts
Call options by funds: $1.57M | Put options by funds: $3.71M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
10%
downside
Avg. target
$23
125%
upside
High target
$36
260%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 26% 1-year accuracy 39 / 152 met price target | 260%upside $36 | Buy Initiated | 23 Dec 2024 |
Rodman & Renshaw Brandon Folkes 46% 1-year accuracy 6 / 13 met price target | 10%downside $9 | Buy Initiated | 14 Nov 2024 |
Financial journalist opinion
Based on 4 articles about OMER published over the past 30 days
Positive
Benzinga
6 days ago
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.
Neutral
Business Wire
6 days ago
Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). Th.
Neutral
Business Wire
2 weeks ago
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual Meeting of the American Society of Hematology (ASH) yesterday in San Diego. The posters, both addressing zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening hematological disorder – d.
Neutral
Business Wire
3 weeks ago
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening hem.
Neutral
Business Wire
1 month ago
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback.
Neutral
Seeking Alpha
1 month ago
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald Serge Belanger - Needham & Company Operator Good afternoon, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Neutral
Business Wire
1 month ago
Omeros Corporation Reports Third Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8.
Neutral
Business Wire
1 month ago
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the.
Neutral
Business Wire
2 months ago
FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy (C3G), an ultra-rare, progressive renal disorder primarily afflicting children and young adults. Caused by dysregulation of the alternative pathway of complement, there is no approved treatment for C3G, which often leads to end-stage renal disease within 10 years of.
Neutral
Seeking Alpha
4 months ago
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Charts implemented using Lightweight Charts™